Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
12 mars 2025 07h30 HE
|
Mesoblast Limited
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that Chief Executive...
Mesoblast Added to S&P/ASX 200 INDEX
06 mars 2025 18h54 HE
|
Mesoblast Limited
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its addition to the...
Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
26 févr. 2025 17h30 HE
|
Mesoblast Limited
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and...
Mesoblast Financial Results and Corporate Update Webcast
25 févr. 2025 18h13 HE
|
Mesoblast Limited
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
Dr. Gregory George MD PhD Joins Mesoblast Board
23 févr. 2025 18h33 HE
|
Mesoblast Limited
NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed...
Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
13 févr. 2025 18h37 HE
|
Mesoblast Limited
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its recently...
Ryoncil® Commercial Launch Update and Product Pipeline
30 janv. 2025 19h11 HE
|
Mesoblast Limited
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the...
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024
30 janv. 2025 18h20 HE
|
Mesoblast Limited
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its...
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
18 déc. 2024 19h08 HE
|
Mesoblast Limited
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers,...
Mesoblast to be Added to Nasdaq Biotechnology Index
18 déc. 2024 07h30 HE
|
Mesoblast Limited
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming addition...